A Platform for the Generation of Targeted, Orally-available Cyclotide Therapeutics
Cyclotides are cyclic peptides that exhibit exceptional stability to extremes of pH, heat, and protease concentration. Their solvent-exposed loops are amenable to mutation, raising the possibility of engineering orally-available mini binders. Some cyclotides exhibit cell entry capability so their target space could include intracellular proteins. To accelerate the development of this exciting new modality, we aim to use yeast surface display to create a platform for the generation of high affinity cyclotide binders to any target protein.